Plain-English translation of NCT06792552 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is one of the first times this treatment has been tested in people.
This is an early-stage trial testing a new experimental medication called SIM0505 in adults with advanced solid tumors that have not responded to standard treatments. Researchers want to find out how safe the medication is, how well the body tolerates it, how the body processes it, and whether it might help shrink tumors. The trial is enrolling people with several different types of advanced cancer, including ovarian, kidney, lung, and uterine cancers.
Many patients with advanced cancers have limited treatment options, especially when their cancer no longer responds to standard therapies like chemotherapy or other approved medications. This trial exists to test whether this new treatment could offer hope to people who have run out of other options.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will receive the medication as an injection every 3 weeks in cycles. During the trial, you'll have regular visits to the study clinic for blood tests, imaging scans, and check-ups to monitor how the treatment is working and whether you're experiencing any side effects. The study will continue for as long as the treatment is helping your cancer and you're tolerating it well.
AI-generated summary from trial data · Aug 20, 2026 · Not medical advice
United States